Novartis: Breast Neoplasms trials

The registry lists 199 Breast Neoplasms studies with Novartis as lead sponsor. 18 are open to participants now and 74 have results posted.

Early Phase 1 1Phase 1 51Phase 2 54Phase 3 48Phase 4 17No phase 43(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid TumorsRecruitingNCT07801508Phase 1
• Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.Not yet recruitingNCT07679269Phase 2
• Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid TumorsRecruitingNCT07660055Phase 1
• Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast CancerRecruitingNCT07604571Phase 1
• Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in ChinaRecruitingNCT07476170
• Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsRecruitingNCT07288359Phase 1/2
• Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsRecruitingNCT07261631Phase 1
• Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.RecruitingNCT07243002
• A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung CancersRecruitingNCT07117214Phase 1
• Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in RussiaRecruitingNCT06930859
• Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world PracticeRecruitingNCT06905301
• A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of RecurrenceRecruitingNCT06830720
• RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi ArabiaRecruitingNCT06797531
• Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid TumorsRecruitingNCT06726148Phase 1/2
• Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal CancersRecruitingNCT06562192Phase 1
• A Post Marketing Surveillance on Piqray in KoreaRecruitingNCT05293470
• Managed Access Programs for LEE011, RibociclibAvailableNCT05038631
• Managed Access Programs for BYL719, AlpelisibAvailableNCT04085653
• A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast CancerCompletedNCT05258747Phase 1Results posted
• Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and FulvestrantTerminatedNCT04899349Phase 2Results posted
• Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With FulvestrantTerminatedNCT04862143Phase 2Results posted
• Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast CancerCompletedNCT03839823Phase 2Results posted
• Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast CancerCompletedNCT03822468Phase 2Results posted
• [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)TerminatedNCT03724253Phase 2Results posted
• Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.CompletedNCT03671330Phase 2Results posted
• Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus FulvestrantTerminatedNCT03439046Phase 3Results posted
• A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase InhibitorCompletedNCT03312738Phase 2Results posted
• Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerCompletedNCT03176238Phase 3Results posted
• Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast CancerCompletedNCT03096847Phase 3Results posted
• Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast CancerCompletedNCT03078751Phase 2Results posted
• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior TreatmentsCompletedNCT03056755Phase 2Results posted
• A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/RibociclibTerminatedNCT03050398Phase 3Results posted
• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCCompletedNCT02941926Phase 3Results posted
• Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.CompletedNCT02732119Phase 1/2Results posted
• 99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast CancerTerminatedNCT02677714Phase 2Results posted
• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.CompletedNCT02437318Phase 3Results posted
• Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.CompletedNCT02422615Phase 3Results posted
• Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast CancerTerminatedNCT02294786Phase 2Results posted
• Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerCompletedNCT02278120Phase 3Results posted
• Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast CancerTerminatedNCT02213042Phase 2Results posted
• LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)CompletedNCT02187783Phase 2Results posted
• Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast CancerCompletedNCT02069093Phase 2Results posted
• Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast CancerCompletedNCT01958021Phase 3Results posted
• Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal WomenCompletedNCT01923168Phase 2Results posted
• A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)TerminatedNCT01919229Phase 2Results posted
• NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast CancerCompletedNCT01816594Phase 2Results posted
• A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.CompletedNCT01783444Phase 2Results posted
• An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker AnalysisCompletedNCT01743560Phase 4Results posted
• Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®CompletedNCT01735175Phase 3Results posted
• A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid TumorsTerminatedNCT01708161Phase 1/2Results posted
• Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast CancerCompletedNCT01698918Phase 2Results posted
• A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORiTerminatedNCT01633060Phase 3Results posted
• A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast CancerCompletedNCT01617668Phase 2Results posted
• Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase InhibitorCompletedNCT01610284Phase 3Results posted
• A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K ActivationCompletedNCT01572727Phase 2/3Results posted
• Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast CancerTerminatedNCT01528345Phase 2Results posted
• Phase III Study Comparing the Efficacy and Safety of EP2006 and FilgrastimCompletedNCT01519700Phase 3Results posted
• Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-FilgrastimCompletedNCT01516736Phase 3Results posted
• Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating FactorCompletedNCT01459653Results posted
• Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast CancerCompletedNCT01231659Phase 2Results posted
• A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast CancerCompletedNCT01160211Phase 3Results posted
• Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast CancerTerminatedNCT01132664Phase 1/2Results posted
• Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer PatientsCompletedNCT01129336Phase 4Results posted
• Lapatinib in Combination With VinorelbineCompletedNCT01013740Phase 2Results posted
• Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast CancerCompletedNCT01007942Phase 3Results posted
• Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast CancerCompletedNCT00876395Phase 3Results posted
• Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or AnastrozoleCompletedNCT00863655Phase 3Results posted
• Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast CancerCompletedNCT00820222Phase 3Results posted
• Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBCCompletedNCT00709761Phase 2Results posted
• Rheumatological Evaluation of Anastrozole and Letrozole as Adjuvant Treatment in Post-menopausal Women With Breast CancerCompletedNCT00688909Phase 4Results posted
• Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast CancerCompletedNCT00667251Phase 3Results posted
• A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After TrastuzumabTerminatedNCT00567879Phase 1/2Results posted
• Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) StudyCompletedNCT00553358Phase 3Results posted
• Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From ChinaTerminatedNCT00508274Phase 3Results posted
• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063DCompletedNCT00490139Phase 3Results posted
• Lapatinib and Bevacizumab for Metastatic Breast CancerCompletedNCT00444535Phase 2Results posted
• Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast CancerCompletedNCT00426556Phase 1Results posted
• Efficacy and Safety of Letrozole vs. Letrozole Plus Zoledronic Acid as Endocrine Therapy Before Surgery in Postmenopausal Patients With Breast CancerTerminatedNCT00375752Phase 4Results posted
• The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone LossCompletedNCT00375505Phase 3Results posted
• Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone LesionsCompletedNCT00375427Phase 3Results posted
• A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone LossTerminatedNCT00333229Phase 4Results posted
• Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast CancerCompletedNCT00332709Phase 3Results posted
• Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast CancerCompletedNCT00320710Phase 3Results posted
• Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2CompletedNCT00281658Phase 3Results posted
• ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and LapatinibTerminatedNCT00272987Phase 3Results posted
• Lapatinib for Brain Metastases In ErbB2-Positive Breast CancerCompletedNCT00263588Phase 2Results posted
• Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast CancerCompletedNCT00248170Phase 3Results posted
• A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast CancerCompletedNCT00171704Phase 3Results posted
• Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.CompletedNCT00171340Phase 3Results posted
• The Use of Zoledronic Acid to Prevent Cancer-treatment Bone Loss in Post-menopausal Women Receiving Adjuvant Letrozole for Breast CancerCompletedNCT00171314Phase 3Results posted
• Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast CancerCompletedNCT00073528Phase 3Results posted
• Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal TherapyCompletedNCT00050011Phase 3Results posted
• A Real-World Study of Treatment Patterns, Tolerability and Effectiveness of CDK4/6 Inhibition in HR+, HER2-negative Metastatic Breast Cancer PatientsCompletedNCT07760714
• A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer PatientsActive, not recruitingNCT07710716
• A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 InhibitorsCompletedNCT07647042
• Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid TumorsWithdrawnNCT07570966Phase 1/2
• A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 InhibitorsCompletedNCT07512063
• Epidemiology and Treatment of HR+/HER2- Breast Cancer in EnglandCompletedNCT07498413
• A Real-world Study of Indian Patients With Advanced Breast Cancer Treated With RibociclibCompletedNCT07363434
• Treatment Landscape and Real-World Dosing Patterns With CDK4/6 Inhibitors for Breast Cancer in PortugalCompletedNCT07223476